glp-1 landscape Battle of delivery technologies GLP-1 Agonists Market Report 2025-2033,
Description
The STRIDE trial evaluated semaglutide in patients with T2DM and PAD, finding a 13% improvement in maximum walking distance and a significant increase in ankle-brachial index, indicating improved perfusion
Previous studies have identified advanced age as a major risk factor for the development of both peripheral vestibular disorders and hearing impairment [16, 23]
26 , e13885 (2025)
Liraglutide is the best studied in psychiatric populations and came off patent in December 2023, but the downside is that it requires daily injections
10.1111/dom.12748 [DOI] [PMC free article] [PubMed] [Google Scholar] 20
No unexpected safety signals emerged
